Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

(2014) Yasuhide Kitagawa et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The utility of prostate-specific antigen in the management of advanced prostate cancer

(2013) E. David Crawford et al.   BJU INTERNATIONAL

Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy

(2011) Shu-Pin Huang et al.   Aging Male

Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy

(2011) Shu-Pin Huang et al.   PROSTATE

Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

(2011) T Sasaki et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer

(2010) S. Hori et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

(2009) Toni K. Choueiri et al.   CANCER

Time to Prostate-Specific Antigen Nadir After Androgen Suppression Therapy for Postoperative or Postradiation PSA Failure and Risk of Prostate Cancer-Specific Mortality

(2008) Christine S. Chung et al.   UROLOGY